ClinicalTrials.gg
RecruitingNCT05725291Updated Aug 17, 2025

AMT-116 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of AMT-116 in Advanced Solid Tumor, sponsored by Multitude Therapeutics Inc.. Recruiting at 10 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-17.

Sponsored by Multitude Therapeutics Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-116, in Patients with Advanced Solid Tumors

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Multitude Therapeutics Inc. is the lead sponsor of 8 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients must be willing and able to sign the ICF, and to adhere to the study visit schedule and other protocol requirements.
  • Age ≥18 years (at the time consent is obtained).
  • Patients with confirmed, unresectable advanced solid tumor. Preferred tumor types include head and neck, non-small cell lung, esophageal, pancreatic, large cell lung, colorectal, cervical, breast, bladder, gastric, biliary tract, skin squamous cell, liver, and basal cell cancer.
  • Patients who have undergone at least one systemic therapy and have radiologically or clinically determined progressive disease during or after most recent , and for whom no further standard therapy is available, or who are intolerable to standard therapy.
  • Patients must have at least one as per version 1.1.
  • (ECOG) performance status of 0-1.
  • Both male and female patients must agree to use effective methods.
  • Patients must have adequate organ function.
  • Women of (WCBP) must have a negative serum pregnancy test.
  • Male patients must agree to use a latex condom, even if they had a successful vasectomy, while on study treatment and for at least 12 weeks after the last dose of the IMP.
  • Male patients must agree not to donate sperm, and female patients must agree not to donate eggs, while on study treatment and for at least 12 weeks after the last dose of the IMP.
  • Availability of tumour tissue sample (either an or a fresh biopsy material) at screening.

Key Exclusion Criteria:

  • Prior therapy with ADC based on Top1 inhibitor.
  • Central nervous system (CNS) .
  • Active or chronic skin disorder requiring systemic therapy.
  • History of Steven's Johnson's syndrome or Toxic Epidermal Necrolysis syndrome.
  • Active ocular conditions requiring treatment or close monitoring, including, but not limited to: macular degeneration, papilledema, active diabetic retinopathy with macular oedema, wet age-related macular degeneration requiring intravitreal injections, or uncontrolled glaucoma.
  • Persistent toxicities from previous systemic anti-neoplastic treatments of Grade >1.
  • Systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of the IMP.
  • Radiotherapy to lung field at a total radiation dose of ≥20 Gy within 6 months, wide-field radiotherapy (e.g., > 30% of marrow-bearing bones) within 28 days.
  • Major surgery (not including placement of vascular access device or tumor biopsies) within 28 days prior to the first dose of the IMP, or no recovery from side effects of such intervention.
  • Prior or autologous bone marrow transplantation.
  • Significant cardiac disease, such as recent (within six months prior to first dose of the IMP) myocardial infarction or acute coronary syndromes (including unstable angina pectoris), congestive heart failure ( class III or IV), uncontrolled hypertension, uncontrolled cardiac arrhythmias.
  • Pregnant or breast-feeding females.

Note: Other protocol defined Inclusion/Exclusion criteria apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    AMT-116 Dose Escalation

    Drug: AMT-116

Interventions

  • Administered intravenously

06

What researchers measure

Primary outcomes

  1. Recommended Phase 2 Dose (RP2D)

    The RP2D will be determined using dose limiting toxicities (DLTs) and all other available study data

    Time frame: Up to 24 months

  2. Maximum Tolerated Dose (MTD)

    The MTD will be determined using DLTs

    Time frame: Up to 24 months

  3. Type, incidence and severity of Adverse Events

    Safety and tolerability profile assessed by the Common Terminology Criteria for Adverse Events v5.0

    Time frame: Up to 24 months

Secondary outcomes

  1. Overall Response Rate (ORR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Proportion of patients achieving Complete Response (CR) or Partial Response (PR)

    Time frame: Up to 24 months

  2. Disease Control Rate (DCR) according to the RECIST v1.1

    Proportion of patients achieving CR, PR or Stable Disease (SD)

    Time frame: Up to 24 months

  3. Progression-free Survival (PFS)

    Time from date of start of treatment to date of the first progression or death, whichever occurs first.

    Time frame: Up to 24 months

  4. Concentration of anti-drug antibodies (ADA)

    Immunogenicity profile characterized by concentration of ADAs

    Time frame: Up to 24 months

  5. Maximum observed concentration (C[max])

    Pharmacokinetic profile characterized by the maximum observed concentration (C\[max\]) of AMT-116

    Time frame: Up to 24 months

  6. Area under the curve (AUC)

    Pharmacokinetic profile characterized by the area under the curve (AUC) of AMT-116

    Time frame: Up to 24 months

  7. Terminal half-life (t[1/2])

    Pharmacokinetic profile characterized by the terminal half-life (t\[1/2\]) of AMT-116

    Time frame: Up to 24 months

  8. Time to maximum concentration (Tmax)

    Pharmacokinetic profile characterized by the time to maximum concentration (Tmax) of AMT-116

    Time frame: Up to 24 months

07

Study locations

8 of 10 sites recruiting
  • Sarah Cannon Research Institute
    Denver, Colorado 80218, United States
    Not yet recruiting
    • Perez Batista Cesar Augusto · Contact
  • Mary Crowley Cancer Research Centers
    Dallas, Texas 75230, United States
    Recruiting
    • Orr Douglas · Contact
  • University of California San Francisco Cancer Center
    San Francisco, California 94115, American Samoa
    Not yet recruiting
    • Munster Pamela · Contact
  • Carolina BioOncology Institute, LLC
    Cary, North Carolina 28078, American Samoa
    Recruiting
    • Powderly John · Contact
  • Macquarie University Hospital
    Sydney, New South Wales 2109, Australia
    Recruiting
    • Park John · Contact
  • ICON Cancer Centre
    Brisbane, Queensland, Australia
    Recruiting
    • Jermaine Coward · Contact
  • Southern Oncology Clinical Research Unit
    Adelaide, South Australia 5042, Australia
    Recruiting
    • Kichenadasse Ganessan · Contact
  • Alfred Hospital
    Victoria Park, Victoria 3004, Australia
    Recruiting
    • Voskoboynik Mark · Contact
  • Austin Health
    Victoria Park, Victoria 3084, Australia
    Recruiting
    • Parakh Sagun · Contact
  • Cabrini Hospital
    Victoria Park, Victoria 3144, Australia
    Recruiting
    • Richardson Gary · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Dec 2026, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2023
First posted
Feb 13, 2023
StartActual
Jul 25, 2023
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Aug 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05725291
Lead sponsor
Multitude Therapeutics Inc.
Responsible party
Sponsor
First posted
Feb 13, 2023
Start date
Jul 25, 2023
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Aug 17, 2025

Study contacts

Juanjuan Zhu
Contact
juanjuan.zhu@multitudetherapeutics.com
+86 13917933915
Jermaine Coward
principal investigator · Integrated Haematology and Oncology Network

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD44v9 Antibody-drug Conjugate AMT-116

Start the discussion